A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase 2 Completed 37 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.

Evaluation	Drug	Modality	Dose	Route
Background	Tremelimumab	Monoclonal antibody	15 mg/kg	Intravenous